Cambium Bio (ASX:CMB), a clinical-stage regenerative medicine company specialising in ophthalmology and tissue repair, has secured a $2.4 million strategic investment from its major shareholder, Zheng Yang Biomedical Technology.
The investment will be made through the placement of 4,363,637 new fully-paid ordinary shares at $0.55 each, representing a 20% premium to Cambium Bio’s closing price on Jan. 19.
The capital will support the initiation of patient dosing in the pivotal Phase 3 program for Elate Ocular, the company's treatment for dry eye disease.
Following the placement, ZYBT’s shareholding will increase from 28.1% to 39.6%, subject to shareholder approval at a virtual general meeting scheduled for March 16.
Cambium Bio CEO Karolis Rosickas said the investment underscores ZYBT’s confidence in the company’s clinical and commercial prospects and positions Cambium Bio to begin Phase 3 dosing in Q2 2026.
At the time of reporting, Cambium Bio's share price was $0.20.